- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 233/72 - Two oxygen atoms, e.g. hydantoin
Patent holdings for IPC class C07D 233/72
Total number of patents in this class: 106
10-year publication summary
|
3
|
9
|
9
|
8
|
6
|
4
|
8
|
1
|
2
|
2
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Modernatx, Inc. | 1259 |
9 |
| Autifony Therapeutics Limited | 48 |
6 |
| sanofi-aventis | 363 |
6 |
| Takeda Pharmaceutical Company Limited | 2711 |
4 |
| Cv6 Therapeutics (NI) Limited | 32 |
4 |
| Galderma Research & Development | 404 |
3 |
| Medivation Prostate Therapeutics LLC | 16 |
3 |
| Novartis AG | 10741 |
2 |
| F. Hoffmann-La Roche AG | 7945 |
2 |
| Sanofi-Aventis Deutschland GmbH | 2631 |
2 |
| Murata Manufacturing Co., Ltd. | 24621 |
2 |
| Sumitomo Chemical Company, Limited | 9047 |
2 |
| Abbvie Inc. | 1799 |
2 |
| University of South Florida | 1835 |
2 |
| ForeSee Pharmaceuticals Co., Ltd. | 36 |
2 |
| Hinova Pharmaceuticals Inc. | 99 |
2 |
| Hydro-Quebec | 651 |
2 |
| Jiangsu Hengrui Medicine Co., Ltd. | 708 |
2 |
| Kowa Company, Ltd. | 1198 |
2 |
| Shanghai Hengrui Pharmaceutical Co., Ltd. | 643 |
2 |
| Other owners | 45 |